<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02383511</url>
  </required_header>
  <id_info>
    <org_study_id>SMT C11003</org_study_id>
    <nct_id>NCT02383511</nct_id>
  </id_info>
  <brief_title>Modified Diet Trial: A Study of SMT C1100 in Paediatric Patients With DMD Who Follow a Balanced Diet</brief_title>
  <official_title>A Phase 1b Placebo-controlled, Multi-centre, Randomized, Double-blind Dose Escalation Study to Evaluate the Pharmacokinetics (PK) and Safety of SMT C1100 in Patients With Duchenne Muscular Dystrophy (DMD) Who Follow a Balanced Diet</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Summit Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Summit Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Placebo-controlled, multi-centre, randomized, double-blind dose escalation study. The aim is&#xD;
      to evaluate the pharmacokinetics (PK) and safety of SMT C1100 in paediatric patients with&#xD;
      Duchenne Muscular Dystrophy (DMD) who follow a balanced diet.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Objective:&#xD;
&#xD;
      To determine the plasma concentration of SMT C1100 calculated at each time point for each&#xD;
      subject (sample size (n), mean, standard deviation (SD), percentage of coefficient of&#xD;
      variation (%CV), geometric mean, median, minimum, and maximum for the parent and the major&#xD;
      metabolites).&#xD;
&#xD;
      Secondary Objectives:&#xD;
&#xD;
        1. To determine the safety and tolerability of single and multiple oral doses of SMT C1100&#xD;
           in patients with Duchenne Muscular Dystrophy (DMD) by assessing the participants adverse&#xD;
           events, ECG results, vital signs and laboratory tests.&#xD;
&#xD;
        2. To evaluate the diurnal variability in the steady state PK of SMT C1100 calculated at&#xD;
           each time point for each subject (sample size (n), mean, standard deviation (SD),&#xD;
           percentage of coefficient of variation (%CV), geometric mean, median, minimum, and&#xD;
           maximum for the parent and the major metabolites).&#xD;
&#xD;
        3. To evaluate reductions in creatine phosphokinase as a potential pharmacodynamic (PD)&#xD;
           marker of SMT C1100 activity and clinical benefit.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic parameters at different dose levels of SMT C1100</measure>
    <time_frame>28 days</time_frame>
    <description>To determine the plasma concentration of SMT C1100 parent and the major metabolites calculated at each time point for each subject.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of SMT C1100</measure>
    <time_frame>28 days</time_frame>
    <description>To determine the safety and tolerability of single and multiple oral doses of SMT C1100 in patients with Duchenne Muscular Dystrophy (DMD) by assessing the participants adverse events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of plasma CK levels</measure>
    <time_frame>42 days</time_frame>
    <description>To evaluate reductions in plasma creatine phosphokinase as a potential pharmacodynamic (PD) marker of SMT C1100 activity and muscle benefit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters at different dose levels of SMT C1100</measure>
    <time_frame>28 Days</time_frame>
    <description>To determine the plasma concentration of SMT C1100 major metabolites calculated at each time point for each subject.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of SMT C1100</measure>
    <time_frame>28 Days</time_frame>
    <description>To determine the safety and tolerability of single and multiple oral doses of SMT C1100 in patients with Duchenne Muscular Dystrophy (DMD) composite assessment of the participant's ECG results and laboratory tests.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters at different dose levels of SMT C1100</measure>
    <time_frame>28 Days</time_frame>
    <description>To evaluate the diurnal variability in the steady state PK of SMT C1100 calculated at each time point for each subject.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Muscular Dystrophy, Duchenne</condition>
  <arm_group>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Drug: SMT C1100 or placebo 3-treatment (Period 1,2 and 3)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Drug: SMT C1100 or placebo 3-treatment (Period 1,2, and 3)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 3</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Drug: SMT C1100 or placebo 3-treatment (Period 1,2 and 3)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SMT C1100</intervention_name>
    <description>Period 1, SMT C1100 1250 mg BID; Period 2, Placebo BID; Period 3, SMT C1100 2500 mg BID</description>
    <arm_group_label>Sequence 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SMT C1100</intervention_name>
    <description>Period 1, SMT C1100 1250 mg BID; Period 2, SMT C1100 2500 mg BID; Period 3, Placebo BID</description>
    <arm_group_label>Sequence 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SMT C1100</intervention_name>
    <description>Period 1, Placebo BID; Period 2, SMT C1100 1250 mg BID; Period 3, SMT C1100 2500 mg BID</description>
    <arm_group_label>Sequence 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients will be males of any ethnic origin with a genetic diagnosis of DMD.&#xD;
&#xD;
          2. Children between 5 and 13 years of age.&#xD;
&#xD;
          3. A parent/legal guardian must date and sign a written consent on behalf of the patient,&#xD;
             according to International Conference on Harmonisation (ICH) and local regulations.&#xD;
             This person must understand the contents of the consent, requirements of the study and&#xD;
             have had an opportunity to review questions with a medically trained member of the&#xD;
             site study team.&#xD;
&#xD;
          4. The patient is willing to give verbal or written age appropriate assent to&#xD;
             participate.&#xD;
&#xD;
          5. For safety reasons, the patient's parent/legal guardian must have a good understanding&#xD;
             of the English language, which the consent/assent forms are available, and understand&#xD;
             the requirements for reporting of any AE to the Investigator.&#xD;
&#xD;
          6. The patient has 6 months or more stable systemic (Patients using an intermittent&#xD;
             regimen of steroid are allowed to be enrolled) corticosteroid therapy prior to&#xD;
             Screening. Dose modifications for body weight are permitted.&#xD;
&#xD;
          7. The patient or parent is willing to adhere to a balanced diet from 1 week prior to&#xD;
             dosing until the end of the follow-up period.&#xD;
&#xD;
          8. Patients must agree to not have sexual intercourse during the study treatment phases&#xD;
             and until the end of their participation in the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Enrolment or participation in any therapeutic clinical trial within the prior 3 months&#xD;
             or 5 times the half-life (whichever is longer). Prior exposure to SMT C1100 is NOT an&#xD;
             exclusion criterion.&#xD;
&#xD;
          2. Known hypersensitivity to the excipients of the study drug or a previous history of&#xD;
             drug allergy.&#xD;
&#xD;
          3. The patient or parent is unwilling to adhere to a balanced diet from 1 week prior to&#xD;
             dosing until the end of the follow-up period.&#xD;
&#xD;
          4. Is dairy or lactose intolerant, has an allergy to egg or nuts or any other dietary&#xD;
             restrictions that might interfere with the conduct of the study.&#xD;
&#xD;
          5. Is unable to refrain from eating cruciferous vegetables and barbecued (chargrilled)&#xD;
             meat for the duration of the study.&#xD;
&#xD;
          6. Use of prohibited medication within 5 half-lives prior to baseline assessments, unless&#xD;
             otherwise stated in protocol.&#xD;
&#xD;
          7. Need for mechanical ventilation.&#xD;
&#xD;
          8. The patient experiences intermittent or continuous difficulties in swallowing.&#xD;
&#xD;
          9. Non ambulatory.&#xD;
&#xD;
         10. Any clinically significant acute illness within 4 weeks of the start of dose&#xD;
             administration.&#xD;
&#xD;
         11. Any comorbidity that, in the opinion of the Investigator, increases the risk of&#xD;
             participating in the study.&#xD;
&#xD;
         12. Symptomatic cardiomyopathy that in the opinion of the Investigator prohibits&#xD;
             participation in this study.&#xD;
&#xD;
         13. Abnormality in the 12-lead ECG at the Screening visit that, in the opinion of the&#xD;
             Investigator, increases the risk of participating in the study.&#xD;
&#xD;
         14. Any clinically significant medical condition, other than DMD that in the opinion of&#xD;
             the Investigator may increase the risk of participating in the study or interfere with&#xD;
             the interpretation of safety or efficacy evaluations (e.g., concomitant illness,&#xD;
             severe reflux, psychiatric condition or behavioural disorder).&#xD;
&#xD;
         15. The Patient smokes or has exposure to daily passive smoking (including parent/legal&#xD;
             guardian, siblings) so as to minimise environmental factors causing CYP 1A induction.&#xD;
&#xD;
         16. Excessive exercise (Investigator opinion).&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>13 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Heart of England NHS Foundation Trust - Heart Lands Hospital</name>
      <address>
        <city>Birmingham</city>
        <zip>B9 5SS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alder Hey Children's NHS Foundation Trust</name>
      <address>
        <city>Liverpool</city>
        <zip>L12 2AP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Great Ormond Street Hospital for Children NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>WC1N 3JH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Manchester University Hospitals NHS Foundation Trust- Royal Manchester Children's Hospital</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <study_first_submitted>February 4, 2015</study_first_submitted>
  <study_first_submitted_qc>March 3, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 9, 2015</study_first_posted>
  <last_update_submitted>August 25, 2015</last_update_submitted>
  <last_update_submitted_qc>August 25, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 26, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Dystrophies</mesh_term>
    <mesh_term>Muscular Dystrophy, Duchenne</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

